var data={"title":"Bleomycin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bleomycin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5749?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">see &quot;Bleomycin: Drug information&quot;</a> and <a href=\"topic.htm?path=bleomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bleomycin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708640\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is recommended that bleomycin be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pulmonary toxicity: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary fibrosis is the most severe toxicity associated with bleomycin. The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving more than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Idiosyncratic reaction: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with bleomycin.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141845\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Blenoxane;</li>\n      <li>Bleomycin Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045592\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antibiotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045584\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">see &quot;Bleomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The risk for pulmonary toxicity increases with cumulative lifetime dose &gt;400 USP units. <b>International considerations</b>: Dosages below are expressed as USP units; 1 USP unit = 1 mg (by potency) = 1,000 international units (Stefanou 2001). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units. Refer to individual protocols for specific dosage and interval information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: All doses of bleomycin are associated with a minimal emetic potential (Dupuis 2011); no routine prophylaxis is recommended (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Test dose for lymphoma patients:</b> Limited data available: <b>Note:</b> Test doses may not be predictive of a reaction (Lam 2005) and/or may produce false-negative results; some protocols no longer require; refer to institution/protocol specific guidelines. Children and Adolescents: IM, IV, SubQ: Because of the possibility of an anaphylactoid reaction, the manufacturer recommends administering 1 to 2 units of bleomycin before the first 1 to 2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma (combination regimen):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ABVE-PC (intermediate-risk or high-risk Hodgkin lymphoma): Children and Adolescents: IV or SQ: 5 units/m<sup>2</sup> on day 1 and 10 units/m<sup>2</sup> on day 8 of a 21-day cycle for 2 to 4 cycles (in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) (Dharmarajan 2015; Friedman 2014; Schwartz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ABVD (high-risk Hodgkin lymphoma): Children and Adolescents: IV: 10 units/m<sup>2</sup> on days 1 and 15 of a 28-day treatment cycle for 2 to 6 cycles in combination with doxorubicin, vinblastine, dacarbazine (Hutchinson 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BEACOPP (high-risk Hodgkin lymphoma): Children and Adolescents: IV: 10 units/m<sup>2</sup> on day 7 of a 21-day treatment cycle for 2 to 4 cycles in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (Kelly 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stanford V (high-risk Hodgkin lymphoma): Adolescent &ge;16 years: IV: 5 units/m<sup>2</sup>/dose in weeks 2, 4, 6, 8, 10, and 12 of a 12-week treatment cycle for 1 cycle in combination with mechlorethamine, vinblastine, vincristine, doxorubicin, etoposide, and prednisone (Gordon 2013; Horning 2000; Horning 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignant germ cell cancer (combination therapy):</b> Limited data available: PEB regimen (Cushing 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: IV: 0.5 <b>mg</b>/kg on day 1 of a 21-day treatment cycle for 4 cycles in combination with cisplatin and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: IV: 15 units/m<sup>2</sup> on day 1 of a 21-day treatment cycle for 4 cycles in combination with cisplatin and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Test dose for lymphoma patients:</b> IM, IV, SubQ: Because of the possibility of an anaphylactoid reaction, the manufacturer recommends administering 1 to 2 units of bleomycin before the first 1 to 2 doses; monitor vital signs every 15 minutes; wait a minimum of 1 hour before administering remainder of dose; if no acute reaction occurs, then the regular dosage schedule may be followed. <b>Note:</b> Test doses may not be predictive of a reaction (Lam 2005) and/or may produce false-negative results.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma (combination regimens):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ABVD: 10 units/m<sup>2</sup> days 1 and 15 of a 28-day treatment cycle in combination with doxorubicin, vinblastine, and dacarbazine (Straus 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BEACOPP: 10 units/m<sup>2</sup> day 8 of a 21-day treatment cycle in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (Dann 2007; Diehl 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stanford V: 5 units/m<sup>2</sup>/dose in weeks 2, 4, 6, 8, 10, and 12 in combination with mechlorethamine, vinblastine, vincristine, doxorubicin, etoposide, and prednisone (Horning 2000; Horning 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignant pleural effusion:</b> Intrapleural: 60 units as a single instillation; mix in 50 to 100 mL of NS and instill into the pleural cavity via a thoracostomy tube</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: <b>Note:</b> Creatinine clearance should be estimated using the Cockcroft-Gault formula:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 50 mL/minute: Administer 70% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 40 mL/minute: Administer 60% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 30 mL/minute: Administer 55% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 20 mL/minute: Administer 45% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 5 to 10 mL/minute: Administer 40% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aronoff 2007: Continuous renal replacement therapy (CRRT): Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kintzel 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 46 to 60 mL/minute: Administer 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 31 to 45 mL/minute: Administer 60% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, adjustment for hepatic impairment is not necessary (King 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pulmonary changes: Discontinue until determined not to be drug-related.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pulmonary diffusion capacity for carbon monoxide (DL<sub>CO</sub>) &lt;30% to 35% of baseline in adults: Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141823\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 units (1 ea); 30 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 units (1 ea); 30 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141808\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47062016\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">see &quot;Bleomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units (1,000 international units = 1 USP unit).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045596\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, SubQ: Administer at a concentration of 3 to 15 units/mL; may cause pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer IV slowly over at least 10 minutes; may be further diluted for administration by continuous IV  infusion; slower administration may produce less severe pulmonary toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrapleural: Adults: Use of topical anesthetics or opioid analgesia is usually not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130900\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141839\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Stable for 24 hours in NS at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045595\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Palliative treatment of squamous cell carcinoma (of the head and neck, penis, cervix, or vulva), testicular carcinoma, Hodgkin lymphoma, and non-Hodgkin lymphoma; sclerosing agent to control malignant effusions (FDA approved in adults); has also been used in the treatment of germ cell tumors and pediatric Hodgkin lymphoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141898\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bleomycin may be confused with Cleocin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Some products available internationally may have vial strength and dosing expressed as international units or milligrams (instead of units or USP units). Refer to prescribing information for specific strength and dosing information.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units (1,000 international units = 1 USP unit).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141894\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The pathogenesis of respiratory adverse effects is not certain, but may be due to damage of pulmonary, vascular, or connective tissue. Response to steroid therapy is variable and somewhat controversial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Tumor pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (may be dose-related and reversible with discontinuation), atrophic striae, erythema, exfoliation of the skin (particularly on the palmar and plantar surfaces of the hands and feet), hyperkeratosis, hyperpigmentation, localized vesiculation, nailbed changes (may be dose-related and reversible with discontinuation), onycholysis, pruritus, skin rash, skin sclerosis, thickening of skin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, mucositis, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction (including chills, confusion, fever, hypotension, wheezing; onset may be immediate or delayed for several hours; includes idiosyncratic reaction in lymphoma patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Scleroderma (diffuse)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoxia, interstitial pneumonitis (acute or chronic), pulmonary fibrosis, rales, tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, bone marrow depression (rare), cerebrovascular accident, cerebral arteritis, chest pain, coronary artery disease, hepatotoxicity, hyperpigmentation (flagellate), ischemic heart disease, malaise, myocardial infarction, nausea, nephrotoxicity, pericarditis, Raynaud&rsquo;s phenomenon, scleroderma (scleroderma-like skin changes), Stevens-Johnson syndrome, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141830\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to bleomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141812\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: May cause hepatic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Idiosyncratic reaction:<b> [US Boxed Warning]: A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing (similar to anaphylaxis) has been reported in 1% of lymphoma patients treated with bleomycin.</b> Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: <b>[US Boxed Warning]: Occurrence of pulmonary fibrosis (commonly presenting as pneumonitis; occasionally progressing to pulmonary fibrosis) is the most severe toxicity. Risk is higher in elderly patients or patients receiving &gt;400 units total lifetime dose;</b>  other possible risk factors include smoking and patients with prior radiation therapy or receiving concurrent oxygen (especially high inspired oxygen doses). A review of patients receiving bleomycin for the treatment of germ cell tumors suggests risk for pulmonary toxicity is increased in patients &gt;40 years of age, with glomerular filtration rate &lt;80 mL/minute, advanced disease, and cumulative doses &gt;300 units (O&rsquo;Sullivan 2003). Pulmonary toxicity may include bronchiolitis obliterans and organizing pneumonia (BOOP), eosinophilic hypersensitivity, and interstitial pneumonitis, progressing to pulmonary fibrosis (Sleijfer 2001); pulmonary toxicity may be due to a lack of the enzyme which inactivates bleomycin (bleomycin hydrolase) in the lungs (Morgan 2011; Sleijfer 2001), If pulmonary changes occur, withhold treatment and investigate if drug-related. In a study of patients with testicular cancer receiving bleomycin as part of the BEP regimen, pulmonary function testing (including forced vital capacity [FVC], forced expiratory volume in 1 second [FEV<sub>1</sub>], and diffusing capacity of the lungs for carbon monoxide [DLCO]) was performed prior to treatment, before each chemotherapy cycle, and then repeated at 1 year, 3 years, and 5 years during follow up; if the carbon monoxide diffusing capacity corrected for hemoglobin content [DLCOc] decreased more than 25% during therapy (compared with baseline), bleomycin was discontinued to avoid further pulmonary toxicity (Lauritsen 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May cause renal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hodgkin lymphoma: Positron emission tomography/computed tomography (PET/CT) may have a role in determining early response to therapy in patients with Hodgkin lymphoma; a negative interim PET/CT result after 2 cycles may indicate that bleomycin can be safely omitted from the ABVD treatment regimen (Johnson 2016). Longer follow-up is necessary to determine the effect of bleomycin omission on long-term morbidity and mortality in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;50 mL/minute), may require dose adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In children, a younger age at treatment, cumulative dose &ge;400 units/m<sup>2</sup> (combined with chest irradiation), and renal impairment are associated with a higher incidence of pulmonary toxicity (Huang, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; International issues: Some products available internationally may have vial strength and dosing expressed as international units or milligrams (instead of units or USP units). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units. One USP unit of bleomycin = 1 mg (by potency) = 1,000 international units (Stefanou 2001). Refer to prescribing information for specific dosing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; O<sub>2</sub> during surgery:  Use caution when administering O<sub>2</sub> during surgery to patients who have received bleomycin; the risk of bleomycin-related pulmonary toxicity is increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298875\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141817\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13088&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Filgrastim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemcitabine: May enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Bleomycin may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of bleomycin infusion. Additionally, monitor patients more closely for signs/symptoms of bleomycin pulmonary toxicity when used with lenograstim (G-CSF).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Bleomycin may diminish the therapeutic effect of Lipegfilgrastim. Management: Lipegfilgrastim should be administered at least 24 hours after the completion of bleomycin. Consider monitoring for enhanced pulmonary toxicity when bleomycin and lipegfilgrastim are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Bleomycin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141819\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3013953\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. According to the manufacturer, women of childbearing potential should avoid becoming pregnant during bleomycin treatment. The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (Peccatori 2013). When multiagent therapy is needed to treat Hodgkin lymphoma during pregnancy, bleomycin (as a component of the ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] regimen) may be used, starting with the second trimester (Follows 2014; Peccatori 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045591\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pulmonary function tests, including total lung volume, forced vital capacity, diffusion capacity for carbon monoxide; vital capacity, total lung capacity, and pulmonary capillary blood volume may be better indicators of changes induced by bleomycin (Sleifjer 2001), chest x-ray; renal function, hepatic function, vital signs, and temperature initially; CBC with differential and platelet count; check body weight at regular intervals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141811\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bleomycin inhibits synthesis of DNA; binds to DNA leading to single- and double-strand breaks; also inhibits (to a lesser degree) RNA and protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141829\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM, SubQ, and intrapleural administration: 100%, 70%, and 45%, respectively, of IV serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 17.5 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Enzymatic inactivation by bleomycin hydrolase, a cytosolic cysteine proteinase enzyme; bleomycin hydrolase is widely distributed in normal tissues (except for the skin and lungs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: IV: 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM, SubQ, Intrapleural: 30 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~65% [IV], 40% [Intrapleural])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597920\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Children younger than 3 years of age have a higher total body clearance than adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323022\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Bleomycin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 unit (1): $59.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 unit (1): $110.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141832\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bemocin (ZW);</li>\n      <li>Bileco (AR);</li>\n      <li>Blenamax (AU, RU, SG, TW);</li>\n      <li>Blenoxane (BR, EC, EG, ZA);</li>\n      <li>Bleo (HK);</li>\n      <li>Bleocin (AE, BG, CZ, EE, EG, GR, HK, HN, HU, ID, IN, JO, JP, KR, KW, LB, LK, LT, MY, PE, PL, PT, QA, SA, SG, TH, TR, TW, VN);</li>\n      <li>Bleocin-S (MY);</li>\n      <li>Bleocina (UY);</li>\n      <li>Bleocip (ET, LB, ZW);</li>\n      <li>Bleocris (PY);</li>\n      <li>Bleolem (CO, MX, TH);</li>\n      <li>Bleomax (MX);</li>\n      <li>Bleomedac (SK);</li>\n      <li>Bleomicina (ES, IT);</li>\n      <li>Bleomycin (AT, CH, DK, FI, GB, NO, SE);</li>\n      <li>Bleomycin PFI (IL);</li>\n      <li>Bleomycine (BE, FR, LU, NL);</li>\n      <li>Bleomycinum (DE);</li>\n      <li>Bleonko (UA);</li>\n      <li>Blexit (CL);</li>\n      <li>Bloicin-S (PH);</li>\n      <li>Kupbloicin (VN);</li>\n      <li>Lyoble (LK);</li>\n      <li>Naprobleo (ET);</li>\n      <li>Naproplat (ET)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 97.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleomycin [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; October 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carver JR, Shapiro CL, Ng A, et al, &ldquo;American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects,&rdquo; <i>J Clin Oncol</i>, 2007, 25(25):3991-4008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/17577017/pubmed\" target=\"_blank\" id=\"17577017\">17577017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cushing B, Giller R, Cullen JW, et al, &quot;Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study &minus; Pediatric Oncology Group 9049 and Children's Cancer Group 8882,&quot; <i>J Clin Oncol</i>, 2004, 22(13):2691-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/15226336/pubmed\" target=\"_blank\" id=\"15226336\">15226336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dann EJ, Bar-Shalom R, Tamir A, et al, &quot;Risk-Adapted BEACOPP Regimen Can Reduce the Cumulative Dose of Chemotherapy for Standard and High-Risk Hodgkin Lymphoma With No Impairment of Outcome,&quot; <i>Blood</i>, 2007, 109(3):905-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/17018856/pubmed\" target=\"_blank\" id=\"17018856\">17018856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/25542311/pubmed\" target=\"_blank\" id=\"25542311\">25542311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diehl V, Franklin J, Pfreundschuh M, et al, &quot;Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,&quot; <i>N Engl J Med</i>, 2003, 348(24):2386-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/12802024/pubmed\" target=\"_blank\" id=\"12802024\">12802024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/23512831 /pubmed\" target=\"_blank\" id=\"23512831 \">23512831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engert A, Franklin J, Eich HT, et al, &quot;Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,&quot; <i>J Clin Oncol</i>, 2007, 25(23):3495-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/17606976/pubmed\" target=\"_blank\" id=\"17606976\">17606976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Follows GA, Ardeshna KM, Barrington SF, et al. Guidelines for the first line management of classical Hodgkin lymphoma.<i> Br J Haematol</i>. 2014;166(1):34-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/24712411 /pubmed\" target=\"_blank\" id=\"24712411 \">24712411 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/25311218/pubmed\" target=\"_blank\" id=\"25311218\">25311218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>J Clin Oncol</i>. 2013;31(6):684-691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/23182987/pubmed\" target=\"_blank\" id=\"23182987\">23182987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horning SJ, Hoppe RT, Breslin S, et al, &quot;Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,&quot; <i>J Clin Oncol</i>, 2002, 20(3):630-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/11821442/pubmed\" target=\"_blank\" id=\"11821442\">11821442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horning SJ, Williams J, Bartlett NL, et al, &quot;Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,&quot; <i>J Clin Oncol</i>, 2000, 18(5):972-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/10694546/pubmed\" target=\"_blank\" id=\"10694546\">10694546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoskin PJ, Lowry L, Horwich A, et al, &quot;Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5390-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/19738111/pubmed\" target=\"_blank\" id=\"19738111\">19738111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang TT, Hudson MM, Stokes DC, et al, &ldquo;Pulmonary Outcomes in Survivors of Childhood Cancer: A Systematic Review,&rdquo; <i>Chest</i>, 2011, 140(4): 881-901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/21415131/pubmed\" target=\"_blank\" id=\"21415131\">21415131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hutchinson RJ, Fryer CJ, Davis PC, et al, &quot;MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,&quot; <i>J Clin Oncol</i>, 1998, 16(3):897-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/9508171/pubmed\" target=\"_blank\" id=\"9508171\">9508171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ibrahimi OA and Anderson RR, &quot;Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation,&quot; <i>N Engl J Med</i>, 2010, 363(24):e36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/21142531/pubmed\" target=\"_blank\" id=\"21142531\">21142531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson PW, Radford JA, Cullen MH, et al, &quot;Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),&quot; <i>J Clin Oncol</i>, 2005, 23(36):9208-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/16314615/pubmed\" target=\"_blank\" id=\"16314615\">16314615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Blood</i>. 2011;117(9):2596-2603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/21079154/pubmed\" target=\"_blank\" id=\"21079154\">21079154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Oncologist</i>, 2001, 6(2):162-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/11306728/pubmed\" target=\"_blank\" id=\"11306728\">11306728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &quot;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&quot; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kung FH, Schwartz CL, Ferree CR, et al, &quot;POG 8625: A Randomized Trial Comparing Chemotherapy With Chemoradiotherapy for Children and Adolescents With Stages I, IIA, IIIA1 Hodgkin Disease: A Report From the Children's Oncology Group,&quot; <i>J Pediatr Hematol Oncol</i>, 2006, 28(6):362-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/16794504/pubmed\" target=\"_blank\" id=\"16794504\">16794504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam MS, &quot;The Need for Routine Bleomycin Test Dosing in the 21st Century,&quot; <i>Ann Pharmacother</i>, 2005, 39(11):1897-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/16219896/pubmed\" target=\"_blank\" id=\"16219896\">16219896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauritsen J, Kier MG, Bandak M, et al. Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin. <i>J Clin Oncol</i>. 2016;34(13):1492-1499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/26903578/pubmed\" target=\"_blank\" id=\"26903578\">26903578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(Suppl 6):vi160-170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/23813932 /pubmed\" target=\"_blank\" id=\"23813932 \">23813932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/19584400/pubmed\" target=\"_blank\" id=\"19584400\">19584400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stefanou A, Siderov J, Society of Hospital Pharmacists of Australia Committee of Specialty Practice in Oncology. Medical errors. Dosage nomenclature of bleomycin needs to be standardised to avoid errors. <i>BMJ</i>. 2001;322(7299):1423-1424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/11417551/pubmed\" target=\"_blank\" id=\"11417551\">11417551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Straus DJ, Portlock CS, Qin J, et al, &quot;Results of a Prospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for Stages I, II, and IIIA Nonbulky Hodgkin Disease,&quot; <i>Blood</i>, 2004, 104(12):3483-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-pediatric-drug-information/abstract-text/15315964/pubmed\" target=\"_blank\" id=\"15315964\">15315964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13088 Version 132.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708640\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F141845\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045592\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045584\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F141823\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F141808\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F47062016\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045596\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130900\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F141839\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045595\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F141898\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F141894\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F141830\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F141812\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298875\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F141817\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F141819\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3013953\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045591\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F141811\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F141829\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597920\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323022\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F141832\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13088|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">Bleomycin: Drug information</a></li><li><a href=\"topic.htm?path=bleomycin-patient-drug-information\" class=\"drug drug_patient\">Bleomycin: Patient drug information</a></li></ul></div></div>","javascript":null}